Regen BioPharma, Inc.
RGBP
$0.01
$0.0020.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 53.51% | -25.80% | 43.67% | -10.35% | 33.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.97% | -40.24% | 7.68% | -33.77% | 22.19% |
| Operating Income | -44.15% | 62.22% | -12.07% | 50.00% | -44.50% |
| Income Before Tax | -111.49% | -28.59% | 84.16% | -255.69% | 16.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -111.49% | -28.59% | 84.16% | -255.69% | 16.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.49% | -28.59% | 84.16% | -255.69% | 16.71% |
| EBIT | -44.15% | 62.22% | -12.07% | 50.00% | -44.50% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 71.12% | 77.35% | 96.98% | -211.17% | -72.62% |
| Normalized Basic EPS | 71.20% | 77.20% | 96.77% | -211.11% | -48.81% |
| EPS Diluted | 71.12% | 77.35% | 96.98% | -211.17% | -72.62% |
| Normalized Diluted EPS | 71.20% | 77.20% | 96.77% | -211.11% | -48.81% |
| Average Basic Shares Outstanding | 630.93% | 463.71% | 424.41% | 14.30% | -44.06% |
| Average Diluted Shares Outstanding | 630.93% | 463.71% | 424.41% | 14.30% | -44.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |